Tilray, Inc. Share Price Toronto S.E.
Equities
APHA
CA03765K1049
Pharmaceuticals
Sales 2024 * | 783M 1.07B 62.12B | Sales 2025 * | 864M 1.18B 68.59B | Capitalization | 1.68B 2.3B 134B |
---|---|---|---|---|---|
Net income 2024 * | -226M -308M -17.94B | Net income 2025 * | -85M -116M -6.75B | EV / Sales 2024 * | 2.38 x |
Net Debt 2024 * | 178M 243M 14.13B | Net Debt 2025 * | 108M 148M 8.61B | EV / Sales 2025 * | 2.08 x |
P/E ratio 2024 * |
-6.36
x | P/E ratio 2025 * |
-14.8
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Tilray, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 29/04/21 |
Carl Merton
DFI | Director of Finance/CFO | - | 29/04/21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 29/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 29/04/21 |
David Clanachan
BRD | Director/Board Member | 62 | 29/04/21 |
Walter Robb
BRD | Director/Board Member | 70 | 29/04/21 |
1st Jan change | Capi. | |
---|---|---|
+31.81% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+16.08% | 239B | |
+10.26% | 210B | |
-7.44% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |